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(57) ABSTRACT 
Stilbene analogs and pharmaceutical compositions that are 
useful for the treatment of various cancers, including Without 
limitation, colorectal cancer (CRC) and breast cancer are 
disclosed. Such stilbene analogs include, for example, com 
pounds of the following formula: 
wherein R“, Rb, R4, R6, R7, R9 and R10 are all H; R2 and R3 are 
independently H, halo, amino, alkylamino, dialkylamino, 
N-oxides of dialkylamino, arylalkylamino, trialkylammo 
nium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, cyano, 
alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, sulfonamide, 
CONR11R12> NR11CO(R13), NR11COO(R13) or 
NRUCONRURB; R11, R12 and R13, are inde endently, H, 
alkyl, aryl, heteroaryl or a ?uorine; R8 is NRCR Z wherein R” 
is H, alkyl, alkoxy, aryl or heteroaryl, Rd is an alkyl group, Z 
is a an unshared pair of electrons, H, alkyl or oxygen; and R1 
and R5 are halogen. 
13 Claims, 18 Drawing Sheets 
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1 
STILBENE ANALOGS AND METHODS OF 
TREATING CANCER 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims the bene?t of both US. Provisional 
Application No. 61/437,341 ?led Jan. 28, 2011 and US. 
Provisional Application No. 61/439,118, ?led Feb. 3, 2011, 
the entire disclosures of Which are both hereby incorporated 
by reference herein. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention Was made With government support under 
2P20 RR020171 aWarded by The National Institutes of 
Health. The government has certain rights in the invention. 
SEQUENCE LISTING 
The instant application contains a Sequence Listing Which 
has been submitted in ASCII format via EFS-Web and is 
hereby incorporated by reference in its entirety. Said ASCII 
copy, created on Mar. 20, 2012, is named SEQUENCE LIS 
TING.txt and is 5.20 kilo bytes in siZe. 
TECHNICAL FIELD 
The present disclosure is directed to compounds having 
antineoplastic activity. In particular, the disclosure is directed 
to halogenated stilbene analogs and methods of identifying 
the speci?c molecular target of the stilbene analogs and inhib 
iting cancer cell groWth in a patient by administering the 
stilbene analogs to the patient. Additionally, the present dis 
closure is directed to the direct target of stilbene analogs, 
methionine adenosyltransferase 2A (MAT2A), and methods 
of detecting the levels of MAT2A in a complex protein mix 
ture. 
BACKGROUND 
Resveratrol (trans- or (E)-3,5,4'-trihydroxystilbene (1)) 
(FIG. 1) is a phytoalexin produced in plants and popularized 
as a bene?cial ingredient of red Wine. Resveratrol, its cis- or 
(Z)-isomer (2), and another stilbene derivative, pterostilbene 
(3), exhibit some anti-cancer activity. (FIG. 1) Recently, We 
found that resveratrol and pterostilbene, a stilbene found in 
blueberries, inhibit colon cancer cells at least partially 
through inhibiting Wnt/[3-catenin signaling. Zhang, W. et al., 
JMed Chem 2011,54, 1288-97. 
Wnt/[3-catenin signaling plays an important role in devel 
opment and tumorigenesis, and the deregulation of Wnt sig 
naling results in formation of tumors. Over 90% of colorectal 
cancers contain a mutation in APC or [3-catenin, and these 
mutations stabiliZe [3-catenin and activate Wnt signaling. 
Cells containing these mutations constitutively activate Wnt 
signaling and undergo strong proliferation that ultimately 
leads to cancer. Intercepting and blocking the Wnt/[3-catenin 
pathWay at various points in the signaling cascade is an attrac 
tive target for colon cancer chemoprevention and therapeu 
tics. 
Several Wnt inhibitors have been identi?ed that target the 
upstream signaling of [3-catenin and promote [3-catenin deg 
radation. Although these agents inhibit Wnt signaling in nor 
mal cells and some APC-mutated colon cancer cells, they 
may not be effective in colon cancer cells containing [3-cate 
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2 
nin mutations. Several other Wnt inhibitors have also been 
reported. HoWever, side effects limit their potential use in 
humans. Natural products found in foods are potentially ideal 
chemopreventive and therapeutic agents for cancer if they 
possess su?icient potency and minimal toxicity. 
Therefore, there is an ongoing need for compounds that are 
more potent than resveratrol and ptero stilbene and that can be 
used to treat cancer and other ailments. There is also a par 
ticular need for compounds that do not exhibit deleterious 
side effects. 
SUMMARY OF THE DISCLOSURE 
Advantages of the present disclosure include halogenated 
stilbene analogs and compositions having antineoplastic 
activity and methods of inhibiting cancer cell groWth and/or 
treating cancer in a patient by administering one or more of 
the halogenated stilbene analogs or compositions. 
One aspect of the present disclosure is directed to haloge 
nated stilbene analogs that are useful for killing hyperprolif 
erating cells such as cancer cells for the treatment of human 
malignant and benign cancers, including Without limitation, 
colorectal cancer (CRC), liver and breast cancer. In this 
aspect of the disclosure, there are provided certain haloge 
nated stilbene analogs having anti-neoplastic activity against 
cancerous cells. The halogenated stilbene analogs of the 
present disclosure include compounds according to formula 
(I): 
XiArl-CR":CRbiAr2 (I) 
Wherein R“ and Rh are independently H, alkyl, halo, alkoxy, 
cyano; X represents at least one halogen, e.g., a ?uorine, 
chlorine, bromine, or iodine substituent, on Arl; each of Arl 
and Ar2 are aryl, e.g., phenyl, naphthyl, and heteroaryl, e.g., 
pyridyl, pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl, 
Which can be further substituted With halo, amino, alky 
lamino, dialkylamino, arylalkylamino, N-oxides of dialky 
lamino, trialkylammonium, mercapto, alkylthio, alkanoyl, 
nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, 
sulfonyl, sulfonamide, CONRl lR12, NR1lCO(Rl3), 
NRllCOO(R13), NRUCONRIZRl3 Where R11, R12, R13, are 
independently, H, alkyl, aryl, heteroaryl or a ?uorine; pro 
vided that Ar2 contains at least one nitrogen atom in the aryl 
ring or at least one nitrogen substituent on the aryl ring; e. g., 
an NRCRdZ substituent Where RC is H, alkyl, alkoxy, aryl, 
heteroaryl, Rd is an alkyl group, Z is a an unshared pair of 
electrons, H, alkyl, oxygen; or a pharmaceutically acceptable 
salt thereof. 
In another embodiment of the present disclosure, the halo 
genated stilbene analogs include compounds of formula (II): 
(11) 
or a pharmaceutically acceptable salt thereof, Wherein each of 
R“ and Rb are as de?ned above; 
Rl to R10 are independently H, halo, amino, alkylamino, 
dialkylamino, N-oxides of dialkylamino, arylalkylamino, 
dialkyloxyamino, trialkylammonium, mercapto, alkylthio, 
alkanoyl, nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, het 


























